Gene clues could personalize Crohn's treatment
NCT ID NCT07263477
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at whether differences in the IL-7 receptor gene are linked to the risk of developing Crohn's disease and how well patients respond to the drug infliximab. Researchers analyzed genetic samples from 303 Crohn's patients and 514 healthy people. The goal is to better understand who might benefit most from this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- infliximab
- What this could lead to
- If successful, this could help identify which Crohn's patients are more likely to benefit from infliximab, enabling more personalized treatment.
- What could go wrong
- This is a retrospective, observational study, not a controlled trial. The findings are preliminary and need confirmation in larger, prospective studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tree mushroom drink calm inflammatory bowel disease?
- Which diet do IBD patients prefer? intermittent fasting, mediterranean, or low FODMAP?
- Can better detection of precancerous lesions in IBD prevent colorectal cancer?
- Which biologic best stops Crohn's from coming back after surgery?
- New biologic mirikizumab put to the test against standard therapies for IBD
- Blood and stool tests could revolutionize IBD monitoring